1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose

出版年份 2016 全文链接

标题

作者

关键词

出版物

Volume 11, Issue 4, Pages S113

出版商

Elsevier BV

发表日期

2016-04-16

DOI

10.1016/s1556-0864(16)30243-x

Discuss science. Find collaborators. Network.

Join a conversation

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started